A judge has given Generic Health more time to file its evidence in a multimillion-dollar dispute with drug makers Otsuka and Bristol-Myers Squibbs over the delayed launch of generic versions of their antipsychotic drug Abilify, but warned there had to be a cut-off point for preparing the decade-long dispute for trial.
US-based firm Jones Day has snagged one of Perth’s top energy litigators from rival Quinn Emanuel to bolster its global disputes team.
The companies behind the top selling Abilify medication have lost their latest bid for documents from the Commonwealth in a multimillion dollar dispute over the delayed listing of generic versions of their drug, with a judge saying the material could be only “of the most marginal relevance”.
Petrol station operator Ampol has denied accusations by US oil giant Chevron that it is misusing Caltex branding on 175 of its service stations, on the first day of a trial that could see the presiding judge take a road trip to view the alleged offending signage firsthand.
A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.
Generic pharmaceutical company Sandoz has hit back in an intellectual property lawsuit by Merck Sharp & Dohme, filing a cross-claim that seeks to undo an extension of time granted to the US drug manufacturer for a patent relating to its multibillion dollar Januvia and Janumet diabetes drugs.
Pharmaceutical companies Sanofi and Bristol-Myers Squibb are liable for losses to the federal government for excess subsidies it allegedly paid for the blood-thinner Plavix after an unjustified court injunction prevented the release of a generic version of the top-selling drug, an appeals court has heard.
US pharmaceutical giant Merck Sharp & Dohme has taken Sandoz to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Janumet and Januvia.
A trade mark dispute between US oil giant Chevron and Australian petrol station operator Ampol has been set down for an expedited hearing in April, ahead of which the companies have been ordered into mediation.
A judge has told a unit of US energy giant Chevron Corporation to consider narrowing its trade mark dispute against Australian petrol station operator Ampol, as the parties consider whether to take the matter to an expedited hearing.